Menu Search
Equities

Sanofi SA

SAN:PAR

Sanofi SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)88.27
  • Today's Change-0.31 / -0.35%
  • Shares traded61.59k
  • 1 Year change-10.79%
  • Beta0.4994
Data delayed at least 15 minutes, as of May 29 2024 08:28 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 15-Jun-23
  • 14-Mar-24
  • 18-Apr-24
  • 16-May-24
  • 23-May-24
Select bar for recommendation details.
Recommendations23-May-24
Buy10
Outperform11
Hold5
Underperform1
Sell0

Share price forecast in EUR

The 25 analysts offering 12 month price targets for Sanofi SA have a median target of 105.00, with a high estimate of 125.00 and a low estimate of 80.00. The median estimate represents a 18.54% increase from the last price of 88.58.
High41.1%125.00
Med18.5%105.00
Low-9.7%80.00

Dividends in EUR

In 2023, Sanofi SA reported a dividend of 3.76 EUR, which represents a 5.62% increase over last year. The 20 analysts covering the company expect dividends of 3.85 EUR for the upcoming fiscal year, an increase of 2.34%.
Div growth (TTM)5.62%
More ▼

Earnings history & estimates in EUR

On Apr 25, 2024, Sanofi SA reported 1st quarter 2024 earnings of 1.78 per share. This result was in line with the consensus of the 9 analysts following the companyand under-performed last year's 1st quarter results by 17.59%.
The next earnings announcement is expected on Jul 25, 2024.
Average growth rate-0.14%
Sanofi SA reported annual 2023 earnings of 8.11 per share on Feb 01, 2024.
Average growth rate+8.47%
More ▼

Revenue history & estimates in EUR

Sanofi had 1st quarter 2024 revenues of 10.46bn. This bettered the 10.40bn consensus of the 9 analysts covering the company. This was 2.37% above the prior year's 1st quarter results.
Average growth rate+1.16%
Sanofi had revenues for the full year 2023 of 43.07bn. This was 0.17% above the prior year's results.
Average growth rate+4.64%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.